- Home
- EBR vs BIIB Comparison
EBR vs BIIB Comparison
Compare EBR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBR
- BIIB
- Stock Information
- Founded
- EBR 1962
- BIIB 1978
- Country
- EBR Brazil
- BIIB United States
- Employees
- EBR N/A
- BIIB N/A
- Industry
- EBR Electric Utilities: Central
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- EBR Utilities
- BIIB Health Care
- Exchange
- EBR Nasdaq
- BIIB Nasdaq
- Market Cap
- EBR 21.7B
- BIIB 18.7B
- IPO Year
- EBR N/A
- BIIB 1991
- Fundamental
- Price
- EBR $10.08
- BIIB $143.06
- Analyst Decision
- EBR
- BIIB Buy
- Analyst Count
- EBR 0
- BIIB 25
- Target Price
- EBR N/A
- BIIB $183.05
- AVG Volume (30 Days)
- EBR 1.6M
- BIIB 1.7M
- Earning Date
- EBR 11-06-2025
- BIIB 10-30-2025
- Dividend Yield
- EBR 6.01%
- BIIB N/A
- EPS Growth
- EBR 47.53
- BIIB 31.67
- EPS
- EBR 0.54
- BIIB 10.45
- Revenue
- EBR $8,016,651,737.00
- BIIB $9,997,000,000.00
- Revenue This Year
- EBR $0.73
- BIIB $2.00
- Revenue Next Year
- EBR $9.95
- BIIB N/A
- P/E Ratio
- EBR $18.73
- BIIB $13.68
- Revenue Growth
- EBR 21.96
- BIIB 3.36
- 52 Week Low
- EBR $5.45
- BIIB $110.04
- 52 Week High
- EBR $10.09
- BIIB $191.19
- Technical
- Relative Strength Index (RSI)
- EBR 67.34
- BIIB 47.80
- Support Level
- EBR $9.63
- BIIB $141.70
- Resistance Level
- EBR $9.94
- BIIB $147.48
- Average True Range (ATR)
- EBR 0.20
- BIIB 4.77
- MACD
- EBR -0.05
- BIIB -1.22
- Stochastic Oscillator
- EBR 98.03
- BIIB 26.25
About EBR Centrais Electricas Brasileiras S A (Each representing one Common Share)
Centrais Eletricas Brasileiras SA is engaged in the generation, transmission, and commercialization of electricity in Brazil. The company operates a portfolio of wind, thermal, hydro, and nuclear power plants located throughout the country. Its segments are Generation which consists of the generation of electric energy and the sale of energy to distribution companies and free consumers, and commercialization; Transmission which consists of the transmission of electric energy; and Administration activities mainly represent the Company's cash management, the management of the compulsory loan, and the management of business in SPEs, and others.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.